ArticleBlood2025

Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study.

Max S Topp et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.